Shield Diagnostics shares soar
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Shares in Shield Diagnostics soared 30p to 552.5p after the group reported positive comments on its diagnostic test for heart disease, Associated Factor Twelve, from a Florence conference of cardiologists and haematologists.
The company said that the reception at the conference would help in in ongoing collaborative talks with potential partners for the test, which could be an alternative to cholesterol testing. Earlier this year, shares in the group soared following leaks that the AFT test was a better predictor of heart attacks than the traditional cholesterol test. Shield said yesterday that it could confirm that collaborative talks were pro gressing satisfactorily as were the group's plans to commercialise AFT.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments